Skip to content

Discontinued — last reported Q1 '22

Return on equity at other companies

Opko Health logo
Opko HealthOPK
-16.9%-21.7pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
100.7%+60.3pp
Theravance Biopharma logo
Theravance BiopharmaTBPH
50.2%+36.2pp
HRO
HarrowHROW
-50%+17.5pp
Precigen logo
PrecigenPGEN
-843.6%-1,103pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-32.8%

Other financials

Income statement

See full
Revenue$58.3M+104%
Gross profit$46.3M+86.8%
Operating income-$15.5M+80.4%
Net income-$30.4M+67.8%
EPS (diluted)-$0.37+71.8%

Balance sheet

See full
Cash & equivalents$180.9M-14.8%
Total debt$166.3M-18.3%
Total equity-$337.0M+0.4%
Total assets$305.1M+3.7%

Cash flow

See full
Operating cash flow-$15.6M+81.6%
CapEx$61.0K+239%
Free cash flow-$15.7M+81.5%

Valuation

See full
Market cap$846.21M+16.3%
Enterprise value$831.61M+15.7%
P/S4.1×-4.8×

Profitability

See full
Gross margin84.9%-1.3pp
Operating margin-47.1%-21.9pp
Net margin-76.8%-34.5pp
FCF margin-47.7%-22.1pp

Returns & leverage

See full
Debt / equity5.6×
Current ratio2.2×-1.4×

Where this comes from

Calculated from Phathom Pharmaceuticals, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed May 10, 2022, on SEC EDGAR. View the filing →

Ask your AI about Phathom Pharmaceuticals, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Phathom Pharmaceuticals, Inc.'s return on equity?
Phathom Pharmaceuticals, Inc. (PHAT) reported return on equity of -147.9% in Q1 2022.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.